Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage  by Koh, Young Jun et al.
Cancer Cell
ArticleDouble Antiangiogenic Protein, DAAP, Targeting
VEGF-A and Angiopoietins in Tumor Angiogenesis,
Metastasis, and Vascular Leakage
Young Jun Koh,1,2,9 Hak-Zoo Kim,1,2,9 Seong-Ik Hwang,1,3 Jeung Eun Lee,1,3 Nuri Oh,1,3 Keehoon Jung,1,2 Minah Kim,1,3
Kyung Eun Kim,1,2 Homin Kim,3 Nam-Kyu Lim,5 Choon-Ju Jeon,5 Gyun Min Lee,3,4 Byeong Hwa Jeon,6 Do-Hyun Nam,7
Hoon Ki Sung,8 Andras Nagy,8 Ook Joon Yoo,2 and Gou Young Koh1,2,3,4,7,*
1National Research Laboratory of Vascular Biology and Stem Cells
2Graduate School of Biomedical Science and Engineering
3Department of Biological Sciences
4Graduate School of Nanoscience and Technology
Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 305-701, Korea
5Aprogen Inc., Daejeon, 305-701, Korea
6Department of Physiology, School of Medicine, Chungnam National University, Daejeon, 301-131, Korea
7Institute for Refractory Cancer Research Program, Samsung Medical Center, Sungkyunkwan University School of Medicine,
Seoul, 135-710, Korea
8Department of Molecular Genetics, University of Toronto, Samuel Lunenfeld Research Institute, Mount Sinai Hospital,
Ontario M5G 1X5, Canada
9These authors contributed equally to this study
*Correspondence: gykoh@kaist.ac.kr
DOI 10.1016/j.ccr.2010.07.001SUMMARYTwo vascular growth factor families, VEGF and the angiopoietins, play critical and coordinate roles in tumor
progression and metastasis. A single inhibitor targeting both VEGF and angiopoietins is not available. Here,
we developed a chimeric decoy receptor, namely double anti-angiogenic protein (DAAP), which can simul-
taneously bind VEGF-A and angiopoietins, blocking their actions. Compared to VEGF-Trap or Tie2-Fc, which
block either VEGF-A or angiopoietins alone, we believe DAAP is a highly effective molecule for regressing
tumor angiogenesis andmetastasis in implanted and spontaneous solid tumors; it can also effectively reduce
ascites formation and vascular leakage in an ovarian carcinoma model. Thus, simultaneous blockade of
VEGF-A and angiopoietins with DAAP is an effective therapeutic strategy for blocking tumor angiogenesis,
metastasis, and vascular leakage.INTRODUCTION
The orchestrated actions of multiple growth factors and their
receptors, coreceptors, and binding partners are required for
tumor angiogenesis (Ferrara and Kerbel, 2005; Folkman, 2007).
Of these factors, VEGF-A is a prime molecule responsible for
tumor progression and metastasis by enhancing angiogenesis
and vascular leakage (Ferrara and Kerbel, 2005; Folkman,
2007). Several approaches have been developed to blockSignificance
The effective blockade of tumor angiogenesis and vascular le
shown to be effective in preventing tumor growth and metast
can simultaneously bind VEGF-A and angiopoietins, this stud
angiopoietins is highly effective for reducing tumor angiogen
over the single blockade of VEGF-A or angiopoietins. This pro
to effectively controlling tumor growth and metastasis, and the
molecule, thus presenting a therapeutic protein.VEGF-A action, including blocking antibody, decoy receptor,
and siRNA against VEGF-A, and clinical applications are currently
being tested (Ferraraet al., 2004;Holashetal., 2002;Hurwitz et al.,
2004) (Angiogenesis Inhibitors in Clinical Trials, National Can-
cer Institute, http://www.cancer.gov/clinicaltrials/developments/
anti-angio-table/). When developing therapeutic decoy receptor
proteins, the binding affinity, efficacy, half-life, bioavailability,
molecular size, stability, and effectiveness should be considered
(Holash et al., 2002; Shibuya andClaesson-Welsh, 2006). To fulfillakage with more than a single targeting molecule has been
asis. By developing a double decoy receptor, DAAP, which
y demonstrated that the double blockade of VEGF-A and
esis, metastasis, and vascular leakage, with greater effects
of-of-concept using DAAP introduces a strategic approach
generation of DAAP provides a ‘‘double trap’’ using a single
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Double Antiangiogenic Proteinthese considerations, Holash et al. (2002) developed an elegant
therapeutic VEGF-A decoy receptor protein, VEGF-Trap. VEGF-
Trap is a chimeric protein consisting of the second immunoglob-
ulin-like (Ig-like) domain (Ig2) of VEGFR1, the third Ig-like domain
(Ig3) of VEGFR2, and the Fcportion of human IgG (Fc). VEGF-Trap
exhibits picomolar binding affinity to VEGF-A and displays high
bioavailability in vivo with low extracellular matrix (ECM) binding
and a moderate half-life (Holash et al., 2002). Several studies
(Byrne et al., 2003;Holashet al., 2002;Saishin et al., 2003; Verheul
et al., 2007) indicate that VEGF-Trap not only effectively inhibits
tumor- and ocular-angiogenesis, but also substantially reduces
vascular leakage, which arises from the actions of VEGF-A and
its receptors, mainly VEGFR2 and, to a lesser extent, VEGFR1
in vivo. VEGF-Trap fulfills the most critical points for developing
therapeutic decoy receptor proteins that block VEGF-A in vivo.
However, VEGF-Trap blocks only VEGF-A and placental growth
factor (PlGF) among multiple endothelial growth factors involved
in tumor angiogenesis.
Angiopoietins, in concert with VEGF-A, are another family of
growth factors that modulate tumor angiogenesis mediated
through Tie2 receptor, which is highly expressed in growing blood
endothelial cells (Augustin et al., 2009; Holash et al., 1999; Shim
et al., 2007; Yoshiji et al., 2005). Angiopoietins include four
proteins: Ang-1, Ang-2, Ang-3, and Ang-4. Among them, Ang-2
alone regresses blood vessels, whereas Ang-2 expression
precedes VEGF-A expression in growing tumor vessels and
enhances angiogenesis in the presence of VEGF-A (Holash et al.,
1999). Indeed, accumulating evidence (Augustin et al., 2009;
Huang et al., 2009; Shim et al., 2007) indicates that Ang-2 in
concert with VEGF-A act as promotingmolecules for tumor angio-
genesis andmetastasis. Accordingly, a specific blocking antibody
or peptibody against Ang-2 reduces tumor angiogenesis, and
growth in some tumor models (Brown et al., 2010; Hashizume
et al., 2010; Oliner et al., 2004). In contrast, Ang-1 acts as an inhib-
iting molecule for tumor growth by inhibiting leakage and
enhancing stabilization of tumor vessels (Ahmad et al., 2001).
Moreover, a recent report indicates that endogenous Ang-1 could
lead tonormalization of tumor vessels during selective blockadeof
Ang-2 action (Falcon et al., 2009). However, several reports indi-
cate that the upregulation of Ang-1 and Ang-2 is part of ‘‘angio-
genic rescue’’ when VEGF-A-VEGFR2 signaling is blockaded
during tumor progression, exaggeratingmalignant tumor progres-
sion by increasing local invasion and accelerating metastasis
(Casanovas et al., 2005; Ebos et al., 2009; Huang et al., 2009;
Paez-Ribes et al., 2009). Therefore, we envisioned that a double
blockade of VEGF-A and angiopoietins could effectively inhibit
tumor angiogenesis and metastasis.
Here, we describe a chimeric protein molecule, double anti-
angiogenic protein (DAAP), as a dual decoy receptor for
VEGF-A/PlGF and angiopoietins.
RESULTS
Generation of DAAP
To design a double decoy receptor for VEGF-A and angiopoietin,
weused the Ig2of VEGFR1or Ig2and Ig3ofVEGFR1asaVEGF-A
decoy molecule and the minimal binding domain of ECD-Tie2 as
an angiopoietin decoymolecule (Figure 1A). To identify aminimal
but effective binding domain of the Tie2 receptor for Ang-2,172 Cancer Cell 18, 171–184, August 17, 2010 ª2010 Elsevier Inc.a series of ECD-Tie2 deletion mutations and ELISA binding
assays were used (Figure S1A available online). In ECD-Tie2,
Ig2 is essential for angiopoietin binding, but Ig1 and three
EGF-like domains (E123) seem to be required for stable angio-
poietin binding. The Ig1-Ig2-E123 of Tie2 (amino acids 1–348)
was the effective and minimal size of the Ang-2 binding protein,
and its Ang-2 binding activity was similar to ECD-Tie2, in agree-
ment with previous reports (Macdonald et al., 2006). Importantly,
the Ig1-Ig2-E123 of Tie2 contains 11.7% acidic amino acids and
has a theoretical pI of 6.55. Based on these findings, seven
different combinations of DAAPwere made with different combi-
nations of (Ig2 or Ig2-Ig3 of VEGFR1), (Ig2, Ig1-Ig2, or Ig1-Ig2-
E123 of Tie2) and the Fc portion of the IgG antibody, named
DAAP1-7 (Figure 1B). ELISA analyses revealed that DAAP-1, -2,
-3, -6, and -7 were incapable of binding to both VEGF-A and
Ang-2, whereas DAAP-4 and DAAP-5 were capable of binding
both VEGF-A and Ang-2, indicating that the proper alignment of
the Ig-like domains is required for appropriate binding to the
ligand. We chose DAAP-5, hereafter referred to as DAAP, as
the best candidate because deletion of VEGFR1 Ig3 from
DAAP-4 did not significantly alter its binding character, which is
consistent with previous findings (Davis-Smyth et al., 1996),
and the molecular size of DAAP-5 was less than that of DAAP-4.
Further analyses were done with VEGF-Trap and Tie2-Fc.
Characterization of DAAP
In vitro pull-down assays revealed that DAAP is able to bind to
human (h) VEGF-A165, mouse (m) VEGF-A164, hVEGF-A189,
hVEGF-A121, mPlGF, hAng-2, mAng-2, hAng-1, mAng-3, and
hAng-4, but it is not able to bind to hVEGF-C, VEGF-E, human
angiopoietin-like-2 (hAngptl-2), or mAngptl-4 (Figure 1C). Con-
sistent with previous data (Holash et al., 2002), VEGF-Trap
was able to bind all VEGF-A isoforms tested but not any of the
angiopoietins, whereas Tie2-Fc was able to bind all angiopoie-
tins tested but not any VEGF (Figures 1D and 1E). These data
indicate that DAAP is capable of binding VEGF-A isoforms,
PlGF, and angiopoietin family proteins. Accordingly, DAAP
almost completely inhibited VEGF-A- or Ang-1-induced
VEGFR2 or Tie2 activation in primary cultured endothelial cells
(Figures S1B and S1C). Both DAAP and VEGF-Trap potently
blocked VEGF-A (2.5 nM)-induced proliferation in primary
cultured endothelial cells, with the IC50 (the concentration that
results in half-maximal inhibition) at 0.98 ± 0.08 nM (n = 4) and
1.06 ± 0.13 nM (n = 4), respectively. ELISA analyses revealed
that the binding affinity of DAAP to VEGF-A is roughly three
times lower than that of VEGF-Trap to VEGF-A, whereas the
binding affinity of DAAP to Ang-2 is roughly five times higher
than that of Tie2-Fc to Ang-2 (Figures 1D and 1E). BIAcore
analyses showed similar results (Figure S1D). DAAP is a disul-
fide-linked dimer of approximately 170 kDa (Figure S1E). Five
N-glycosylation and no O-glycosylation sites were predicted in
DAAP (Figure S1F). A deglycosylation assay with several glyco-
sidases indicated that DAAP is an N-glycosylated protein with
terminal sialic acids, but it is not an O-glycosylated protein
(Figure S1G). The N-glycosylation of DAAP does not seem to
be important for its VEGF-A or Ang-2 binding activities. However,
it is essential for the shift of the theoretical pI value (7.7) to an
observed pI value of 6.0 (data not shown). Our ELISA assays
indicated that the preoccupation of one binding site on DAAP
Figure 1. Molecular and Biochemical Characteristics and Pharmacokinetic Profiles of DAAP
(A) Schematic diagrams outlining the protein structure of the extracellular domains (ECD) of VEGFR1 and Tie2.
(B) The binding of seven DAAP variants to VEGF-A and Ang-2, was determined by ELISA and graded by binding affinity: none (), weak (+), moderate (++), and
strong (+++).
(C) In vitrobindingassaybetweenDAAP (DP), VEGF-Trap (VT), or Tie2-Fc (T2) andvariousVEGF isoforms,PlGF, angiopoietins, orAngptls. h, human;m,mouse. The
immunoprecipitates were captured by Protein-A and western blotted with anti-FLAG antibody. Input, input of each recombinant protein loaded for comparison.
(D–F) Comparison of bindings of DAAP, VEGF-Trap, and Tie2-Fc to (B) VEGF-A, (C) Ang-2, or (D) ECMas determined by ELISA. Numbers in (B) and (C) indicate the
binding affinity. Values are mean ± SD (n = 4).
(G) Pharmacokinetic profiles for DAAP. DAAP, VEGF-Trap, or Tie2-Fc (100 mg) was subcutaneously injected into C57BL/6Jmice, blood samples were taken at the
indicated time points, and the serum levels of these proteins were measured by ELISA. Values are mean ± SD (n = 4).
See also Figure S1 and Table S1.
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Double Antiangiogenic Proteinwith VEGF-A or Ang-2 further enhanced its binding activity to the
other ligand- Ang-2 or VEGF-A (Figures S1I–S1L), possibly
through a favorable conformational change, which could be a
supplementary benefit.
DAAP Pharmacokinetics
The theoretical pI of DAAP is 7.7, but isoelectric gel focusing
analysis showed its virtual pI value to be roughly 6.0 (Fig-
ure S1H). In general, therapeutic proteins with higher (>9.0) pI
values display poor pharmacokinetic properties due to the highly
positively charged protein being largely deposited at the site of
subcutaneous injection because of the nonspecific adhesion of
highly negatively charged proteoglycans that comprise the
ECM. To confirm this prediction, an ECM binding assay was per-
formed with increasing concentrations of DAAP, VEGF-Trap,
and Tie2-Fc (Figure 1F). Correlating with the theoretical pI
values, the ECM binding of Tie2-Fc was relatively low. The
ECM binding of DAAP was higher than that of Tie2-Fc but
lower than that of VEGF-Trap in the range of 3–30 nM ECM. Ina standard pharmacokinetic analysis, mice were given single
subcutaneous injections of 100 mg DAAP, VEGF-Trap, or Tie2-
Fc recombinant protein. The half life of DAAP was longer than
Tie2-Fc and VEGF-Trap (Figure 1G). DAAP had a maximal
concentration (Cmax) of 7.89 ± 0.96 mg/ml and a total area under
the curve concentration (AUC) of 19.6 ± 2.4 mg days/ml, VEGF-
Trap had a Cmax of 5.97 ± 0.60 mg/ml and an AUC of 11.9 ±
0.73 mg days/ml, and Tie2-Fc had a Cmax of 8.16 ± 0.92 mg/ml
and an AUC of 10.3 ± 1.02 mg days/ml. Thus, the pharmacoki-
netic profiles followed the theoretical charge predictions and
in vitro ECM adhesion properties, and DAAP had a higher
bioavailability and longer half-life than VEGF-Trap.
Potential Toxicity of DAAP
We examined the potential toxicity of DAAP (25 mg/kg of body
weight, subcutaneous administration every 3 days for 30 days)
by measuring changes in body weight, hematopoietic profile,
renal function, hepatic function, and blood pressure and by
morphological analyses of major organs and blood vesselsCancer Cell 18, 171–184, August 17, 2010 ª2010 Elsevier Inc. 173
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and Tie2-Fc. Overall, no obvious or significant differences were
found except thrombocytosis, hypertension andmicroalbuminu-
ria in response to DAAP and VEGF-Trap compared to PBS, Fc,
and Tie2-Fc (Table S1 and Figures S1M–S1R). Furthermore,
we examined the immune response against DAAP using serum
derived from mice treated with DAAP (25 mg/kg of body weight,
subcutaneous administration every 3 days for 60 days).
However, no notable immune responses against the junction
peptide or the targeting receptors were detected using the
serum (Figures S1S–S1U).
DAAP Suppresses Tumor Growth in the LLC
Implantation Tumor Model
To explore the value of DAAP as an anti-angiogenic therapeutic
molecule and compare it to other effective agents targeting
the VEGF-A or angiopoietins pathway, we evaluated the ability
of DAAP to block tumor growth and angiogenesis in the subcu-
taneously implanted Lewis lung carcinoma (LLC) tumor model.
After implanting 1 3 106 LLC cells, the mice were left for
7 days, allowing a small nodule (200 mm3) to grow. The mice
received subcutaneous injections of 5, 10, 25, and 50 mg/kg of
DAAP, VEGF-Trap, Tie2-Fc, or Fc (as a control) every 3 days
for the subsequent 3 weeks, and the tumor growth was
measured every 6 days. Compared to Fc and Tie2-Fc treatment,
tumor growth was markedly attenuated with DAAP and VEGF-
Trap treatment (Figure S2A). Distinct dose-responses were
observed among 5, 10, and 25 mg/kg DAAP- and VEGF-Trap-
treated animals in the reduction of tumor growth, whereas no
distinct differences were observed between 25 and 50 mg/kg
DAAP- and VEGF-Trap-treated groups (Figure S2A). In compar-
ison, a distinct dose-response curve for tumor growth reduction
was not observed with Tie2-Fc treatment (Figure S2A). Because
25 mg/kg DAAP and VEGF-Trap administration exerted maximal
effect in reducing tumor growth, we chose this dosage for subse-
quent experiments. Compared to Fc treatment, the increase
in tumor volume was reduced 81% by DAAP and 68% by
VEGF-Trap 24 days after treatment (Figure 2A). Nonetheless,
compared to Fc treatment, the ratio of viable versus necrotic
areas in tumors was similarly reduced by DAAP (51%) and by
VEGF-Trap (52%) 24 days after treatment (Figures S2B–D).
Day 31 after tumor implantation, the mice were killed, and the
blood vessels in the tumors and metastatic tumor cells in the
inguinal lymph nodes (LN) were evaluated. In comparison with
Fc treatment, blood vessel densities were 82% less by DAAP
and 58%–60% less by VEGF-Trap in both intratumoral and peri-
tumoral regions (Figures 2B and 2C). Importantly, detailedmicro-
scopic analysis revealed that70%–80%of the blood vessels in
the tumors were pruned with VEGF-Trap treatment, narrowed
with Tie2-Fc treatment, and pruned and narrowed with DAAP
treatment regardless of the tumor region, with the exception of
necrotic regions (Figure 2B). These findings indicate that DAAP
not only regresses VEGF-A-induced active vessel sprouting
and network formation, but also blocks angiopoietins-induced
active vessel enlargement in tumor angiogenesis (Augustin
et al., 2009). Accordingly, more tumor hypoxia was induced by
DAAP than by VEGF-Trap (Figures S2E and S2F), confirming
that DAAP is more effective than VEGF-Trap at inducing tumor
vessel regression and reducing subsequent blood flow in the174 Cancer Cell 18, 171–184, August 17, 2010 ª2010 Elsevier Inc.established tumor. Nevertheless, enhanced invasiveness of the
LLC tumor was not detected at 5 and 10 days after starting treat-
ment with DAAP and VEGF-Trap (Figure S2G). Instead, at least in
the LLC implantation model, both DAAP and VEGF-Trap sup-
pressed invasion into the surrounding skin and muscle layers
(Figure S2G). We further examined the effect of DAAP and
VEGF-Trap in the established LLC tumor (tumor size at start of
treatment was roughly 500 mm3; Figures S2H and S2I). Even
under these circumstances, 60%–70% of blood vessels in the
tumors were pruned with VEGF-Trap treatment but pruned and
narrowed with DAAP treatment (Figure S2I). Accordingly, the
effect of DAAP on antitumor growth in the established LLC tumor
was significantly greater than that of VEGF-Trap (Figures S2H).
To examine the effect of recombinant proteins on LLC metas-
tasis into the sentinel LN, we sampled the inguinal LN 24 days
after treatment. Treatment with DAAP, VEGF-Trap, or Tie2-Fc
reduced metastasis in the order DAAP > VEGF-Trap > Tie2-
Fc > Fc (Figures 2D and 2E).
DAAP Reduces Tumor Growth and Metastasis
in a Melanoma Implantation Model
Wegenerated amelanomamodel by implanting 13 106 B16/F10
melanoma cells into the flank region of C57BL/6J mice. Seven
days later, the mice received subcutaneous injections of
25 mg/kg Fc, DAAP, or VEGF-Trap every 2 days for the subse-
quent 2 weeks and the tumors were sampled. Compared to
Fc treatment, the increases in tumor volume were reduced
57% by DAAP and 28% by VEGF-Trap 2 weeks after treatment
(Figure 3A). In comparisonwith Fc treatment, blood vessel densi-
ties in the intratumoral and peritumoral regions were 82% and
67% less by DAAP and 71% and 46% less by VEGF-Trap
(Figures 3B and 3C). Moreover, in comparison with Fc treatment,
lymphatic vessel density in the peritumoral region was 73% less
by DAAP and 43% less by VEGF-Trap (Figures 3B and 3D).
Compared to Fc treatment, metastasized cytokeratin+ tumor
cells in the inguinal and axillary LN were 94% and 88% less by
DAAP and 62% and 75% less by VEGF-Trap (Figures 3E and
3F). Moreover, the number of tumor colonies (>200 mm in diam-
eter per section) in the lungs was 93% less by DAAP and 55%
less by VEGF-Trap (Figures 3G and 3H).
Combined Therapy with DAAP Plus Cytotoxic Agent
Exerts Markedly Greater Effects Than DAAP Alone
We performed additional experiments to assess the efficacy of
combination therapy with DAAP and a representative cytotoxic
chemotherapy agent compared to DAAP alone. Starting from
7 days after implanting 1 3 106 LLC cells or B16/F10 cells, the
mice were treated with combined subcutaneous injections of
10 mg/kg DAAP or VEGF-Trap and intraperitoneal injections of
10 mg/kg cisplatin or 20 mg/kg dacarbazine (Figure 4 and
Figure S3). Control mice were treated with 10 mg/kg Fc or
each therapeutic individually in the same manner. In all cases,
combined therapy resulted in markedly greater effects than
monotherapy in reducing tumor growth, angiogenesis, and
metastasis to inguinal LN and lung (Figure 4 and Figure S3).
Roughly, combinations of 10 mg/kg DAAP with 10 mg/kg
cisplatin or with 20 mg/kg dacarbazine resulted in antitumor
growth, anti-angiogenic, and anti-metastatic effects similar to
25 mg/kg DAAP alone in both tumor models. Thus, by using
Figure 2. DAAP Reduces Tumor Growth, Vessel Formation, and Metastasis in Implanted LLC Tumors
(A) Comparison of tumor growths. Each group, n = 6. *p < 0.05 versus Fc; #p < 0.05 versus VT. The arrow indicates the start of injections.
(B) Images showing PECAM-1+ blood vessels (red) in the peri- and intratumoral regions. Scale bars represent 200 mm.
(C) Densities of PECAM-1+ blood vessels in the peri- and intratumoral regions. Each group, n = 6. *p < 0.05 versus Fc; #p < 0.05 versus VT.
(D) Images showing the presence of cytokeratin+ LLC cells (green) in the inguinal LN (white arrows) and primary tumors (inlets). Scale bars represent 100 mm and
200 mm (inlets).
(E) Comparison of the metastasis of cytokeratin+ LLC cells in the inguinal LN. The area of cytokeratin+ fluorescence was presented as% per total sectioned area
[Cyto+ area (%)]. Each group, n = 6. *p < 0.05 versus Fc; #p < 0.05 versus T2; $p < 0.05 versus VT. All following values are mean ± SD. DP, DAAP; VT, VEGF-Trap;
Fc, dimeric-Fc (Fc).
See also Figure S2.
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Double Antiangiogenic Proteincombination therapy, the dosage of DAAP for treating cancer
can be reduced by 60% and results in a similar extent of tumor
growth suppression and metastasis inhibition. Equally, the
possible side effects of DAAP and cisplatin or dacarbazine
can be reduced by combination therapy.
DAAP Is Superior to Combined Therapy of VEGF-Trap
Plus Tie2-Fc
To compare the antitumor effect of DAAP with the antitumor
effect of combination treatment with VEGF-Trap and Tie2-Fc,
we determined the dosages for treatment based on molar
mass and similar numbers of each protein binding to VEGF-A
and angiopoietins. Given the estimations, the mice were treatedwith 14 mg/kg DAAP or 12 mg/kg VEGF-Trap plus 22 mg/kg
Tie2-Fc every 3 or 2 days for 2 weeks, starting from 7 days after
implanting 1 3 106 LLC cells or 1 3 106 B16/F10 cells (Figure 5
and Figure S4). Control mice were treated with 12 mg/kg Fc in
the same manner. Compared to VEGF-Trap plus Tie2-Fc,
DAAP had greater antitumor growth, anti-angiogenic, and anti-
metastatic effects in both tumor models (Figure 5 and Figure S4).
DAAP Also Reduces Tumor Growth and Metastasis
in Orthotopically Implanted CT-26-luc Colon Cancer
and Spontaneous Breast Tumor Models
To determine whether DAAP is more uniformly efficacious than
VEGF-Trap in antitumor effect, we compared the efficacy ofCancer Cell 18, 171–184, August 17, 2010 ª2010 Elsevier Inc. 175
Figure 3. DAAP Suppresses Tumor Growth, Vessel Formation, and Metastasis in Melanoma
(A) Comparison of tumor growths. Each group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus VT. The arrow indicates the start of injections.
(B) Images showing PECAM-1+ blood vessels (red) and LYVE-1+ lymphatic vessels (green) in the peri- or intratumoral regions. White dotted-lines indicate the
margin between the tumor and subcutaneous tissues. Scale bars represent 200 mm.
(C and D) The density of blood and lymphatic vessels in the peri- or intratumoral regions. Each group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus VT.
(E) Images showing the presence of cytokeratin+ melanoma cells in the inguinal LN (upper panel) and axillary LN (lower panel). Scale bars represent 1 mm.
(F) A comparison of the metastasis of cytokeratin+ melanoma cells in the LN. The area of cytokeratin+ fluorescence was presented as% per total sectioned area
[Cyto+ area (%)]. Each group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus VT.
(G) Lung sections stained with H&E. Three regions of the lung sections (indicated in the left column) were viewed under high magnification. The arrows indicate
clustered metastatic melanoma. Scale bars represent 5 mm (black) and 200 mm (white).
(H) Comparison of the number of melanoma colonies (>200 mm in diameter) in the lung sections. Each group, n = 5. *p < 0.05 versus Fc; #p < 0.05
versus VT.
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Double Antiangiogenic ProteinDAAP and VEGF-Trap in additional tumor models. We generated
an orthotopic colon cancer model by implanting 1 3 106 CT-
26-luc cells into the dome of the cecal wall of Balb/c mice
(Figure S5). Seven days after implantation, the mice received176 Cancer Cell 18, 171–184, August 17, 2010 ª2010 Elsevier Inc.subcutaneous injections of 25 mg/kg of Fc, VEGF-Trap, or
DAAP every 2 days for the subsequent 3 weeks and the efficacy
of antitumor effect were analyzed (Figure S5). We also used
female MMTV-PyMT mice as a spontaneous breast tumor
Figure 4. Combination Therapy of DAAP
Plus Cisplatin in Implanted LLC Tumors
Seven days after LLC implantation, the mice were
given injections of DAAP + cisplatin (D+C), VEGF-
Trap + cisplatin (V+C), DAAP (DP), VEGF-Trap
(VT), or dimeric-Fc (Fc). The proteins were given
every 3 days and cisplatin was given every
7 days. Tissues were sampled on day 31.
(A) Comparison of tumor growths. Each group,
n = 5. *p < 0.05 versus DP or VT; #p < 0.05 versus
V+C. Arrow indicates the start of injections.
(B and C) Images showing PECAM-1+ blood
vessels (red) in the intra- and peritumoral regions.
White dotted lines indicate themargin between the
tumor and subcutaneous tissues. Scale bars
represent 200 mm.
(D and E) Densities of PECAM-1+ blood vessels
(VD) in the intra- and peritumoral regions. Each
group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus
VT or V+C.
(F) Images showing the presence of cytokeratin+
LLC cells in the axillary LN. Scale bars represent
1 mm.
(G) Comparison of the metastasis of cytokeratin+
LLC cells in the axillary LN. The area of cytokera-
tin+ fluorescence was presented as % per total
sectioned area [Cyto+ area (%)]. Each group,
n = 5. *p < 0.05 versus Fc; #p < 0.05 versus VT or
V+C; $p < 0.05 versus DP or VT.
(H) Lung sections stained with hematoxylin and
eosin. Two regions of the lung sections (indicated
as black lined square in each inset) were viewed
under high magnification. The arrows indicate
clustered metastatic LLC tumors. Scale bars
represent 500 mm.
(I) Comparison of the number of tumor colonies
(>200 mm in diameter) in the lung sections. Each
group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus
VT or V+C; $p < 0.05 versus DP or VT.
See also Figure S3.
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Double Antiangiogenic Proteinmodel (Figure 6). At 10 weeks of age, the mice received
subcutaneous injections of 25 mg/kg Fc, DAAP, or VEGF-Trap
twice per week for the subsequent 5 weeks and the efficacy of
antitumor effect were analyzed (Figure 6). In both tumor models,
the growth, vascular density, and metastasis to the sentinel
lymph node were significantly attenuated by DAAP and
VEGF-Trap compared to Fc (Figure 6 and Figure S5). We noted
that the effects of DAAP on the suppression of tumor growths,
vascular densities, and metastasis to sentinel lymph node
were significantly greater than those of VEGF-Trap in both
tumormodels (Figure 6 and Figure S5). However, enhanced inva-
sion into the surrounding tissues was not detected in either
tumor model at the end of the experiments (Figure 6B and
Figure S5K).Cancer Cell 18, 171–184DAAP Reduces Vascular Leakage
and Induces Tumor Vessel
Normalization in Ovarian
Carcinoma
To explore whether DAAP suppresses
vascular leakage, we generated an
orthotopic OVCA mouse model by im-planting 3 3 107 MDAH-2774 cells into athymic nude mice
(Jeon et al., 2008). Seven days later, 5 ml of ascites was aspi-
rated from the mice, and the mice were given subcutaneous
injections of 25 mg/kg DAAP or VEGF-Trap every 2 days for
the subsequent week. Before sacrificing the mice, Evans blue
and FITC-dextran were intravenously applied to examine
vascular leakage in the peritoneal cavities. Both DAAP and
VEGF-Trap markedly reduced ascites formation compared to
Fc, but we noted that the ascites volume was 73% less by
DAAP and 59% less by VEGF-Trap (Figures 7A and 7B). The
Evans blue dye was markedly visible in the intestine and abdom-
inal wall of the Fc-treated mice, but it was barely visible in the
DAAP-treated mice and was mildly visible in VEGF-Trap treated
mice (Figure 7C). In addition, the ascites of Fc-treated mice was, August 17, 2010 ª2010 Elsevier Inc. 177
Figure 5. DAAP Exerts Greater Antitumor Activities than Combined Therapy of VEGF-Trap and Tie2-Fc in Implanted LLC Tumor Model
LLC implanted mice were given subcutaneous injections of DAAP (DP), VEGF-Trap + Tie2-Fc (VT+T2), or dimeric-Fc (Fc) every 3 days. Tissues were sampled
24 days after treatment.
(A) Comparison of tumor growths. Each group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus VT+T2. Arrow indicates the start of injections.
(B) Images showing PECAM-1+ blood vessels (red) in the intra- and peritumoral regions. White dotted lines indicate the margin between the tumor and subcu-
taneous tissues. Scale bars represent 200 mm.
(C) Densities of PECAM-1+ blood vessels (VD) in the intra- and peritumoral regions. Each group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus VT+T2.
(D) Images showing the presence of cytokeratin+ LLC cells in the axillary LN. Scale bar represents 1 mm.
(E) Comparison of the metastasis of cytokeratin+ LLC cells in the axillary LN. The area of cytokeratin+ fluorescence was presented as % per total sectioned area
[Cyto+ area (%)]. Each group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus VT+T2.
(F) Lung sections stained with hematoxylin and eosin. Three regions of the lung sections (indicated as black lined squares) were viewed under highmagnification.
The arrows indicate clustered metastatic tumors. Scale bars represent 500 mm.
(G) Comparison of the number of tumor colonies (>200 mm in diameter) in the lung sections. Each group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus VT+T2.
See also Figure S4.
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Double Antiangiogenic Proteinhighly hemorrhagic and contained a high level of Evans blue
(304.6 ± 58.4 mg, n = 6), whereas the ascites DAAP-treated
mice was mildly hemorrhagic and contained a low level of Evans
blue (18.2 ± 3.7 mg, n = 6) and the ascites of mice treated with
VEGF-Trap was moderately hemorrhagic and contained
a moderate level of Evans blue (34.6 ± 5.2 mg, n = 6) (Figures
7D and 7E). The leakage measured by FITC-dextran was similar
to that measured by Evans blue (Figures 7F and 7G), confirming
that DAAP is superior to VEGF-Trap in preventing ascites
formation in OVCA.
The dissemination and seeding of primary cancer cells onto
organs in the peritoneal cavity, including the mesentery, is one
of the characteristics of OVCA (Colombo et al., 2006). Consistent
with this character, in this OVCA model, we observed the seed-
ing and growing of tumors in the mesentery (Figure 7H).
Compared to Fc treatment, disseminated tumor volume in the
mesentery was 78% less by DAAP and 35% less by VEGF-
Trap (Figures 7H and 7I). Confocal image analysis of the capillary
beds in themesenteric membranes revealed a robust increase of178 Cancer Cell 18, 171–184, August 17, 2010 ª2010 Elsevier Inc.variably sized and tortuous vessels around the tumor area in
untreated and Fc-treated mice, whereas the increase in
abnormal capillary bedswasmoderate in the VEGF-Trap-treated
mice and improperly developed and regressed capillary beds
were observed around the micro-tumor area in DAAP-treated
mice (Figure 7J). The capillary bed in the peritoneum of the
abdominal wall showed that most capillaries were unorganized,
dense, and chaotic in untreated and Fc-treated mice, whereas
approximately 43% of capillary beds were normalized by
VEGF-Trap and 57% by DAAP. Interestingly, the DAAP-treated
capillary beds were less enlarged and more organized than the
VEGF-Trap-treated capillary beds (Figure 7K). Moreover, the
DAAP-treated mice displayed more well-arranged PECAM-1
distribution in the junction region of the endothelium in the
peritoneum of the abdominal wall and more ghost vessels
(CD31/collagen IV+; Inai et al., 2004) in the mesenteric
membrane than in the VEGF-Trap-treated mice (Figure S6).
Furthermore, we found that MDAH-2774 cell implantation
caused a robust induction of host Ang-2 in the abdominal
Figure 6. DAAP Reduces Tumor Growth,
Vessel Formation, and Metastasis in Spon-
taneous Breast Tumor Model
(A) Comparison of dissected tumor weight.
Each group, n = 4. *p < 0.05 versus Fc; #p < 0.05
versus VT.
(B) Tumor sections stained with hematoxylin and
eosin. Scale bars represent 250 mm.
(C) Images showing PECAM-1+ blood vessels
(red) in tumors. Scale bars represent 200 mm.
(D) Densities of PECAM-1+ blood vessels in
tumors. Each group, n = 4. *p < 0.05 versus Fc;
#p < 0.05 versus VT.
(E) Images showing the presence of cytokeratin+
breast cancer cells in the mediastinal LN. Scale
bar represents 1 mm.
(F) Comparison of the metastasis of cytokeratin+
breast cancer cells in the mediastinal LN. The
area of cytokeratin+ fluorescence was presented
as % per total sectioned area [Cyto+ area (%)].
Each group, n = 4. *p < 0.05 versus Fc; #p < 0.05
versus VT.
See also Figure S5.
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effective than VEGF-Trap in preventing vascular leakage, tumor
dissemination, and progression, and the induction of aberrant
capillary bed normalization most likely occurs via tumor- and
host-derived VEGF-A and Ang-2 in OVCA.
Close Correlation between DAAP Efficacy and
Expression of VEGF-A and Ang-2 in the Tumor Models
The aforementioned findings led us to determine how DAAP
acted dominantly over VEGF-Trap on its target in the tumor
models. Quantitative RT-PCR analyses revealed that the levels
of VEGF-A, VEGFR2, Ang-2, and Tie2 mRNA were markedly
upregulated in endothelial cells of the growing tumors (2 weeks
after implantation of LLC or B16/F10 cells) compared to nonen-
dothelial cells or adjacent normal tissues (Table S2). In contrast,
the level of Ang-1 mRNA was not changed in either the endothe-
lial cells or nonendothelial cells of the growing tumor (Table S2).
Thus, there were close co-relationships between DAAP efficacy
and the expression of VEGF-A, VEGFR2, Ang-2, and Tie2, but
there was no relationship between DAAP efficacy and Ang-1
expression. We also examined the distribution of VEGFR2,
Ang-2, and Tie2 in the tumors by immunohistochemistry and
using a genetically-modified mouse (heterozygous Ang-2+/LacZ)
(Gale et al., 2002) (Figure 8). All of the results obtained from
immunohistochemistry and the Ang-2+/LacZ mice correlated
well with the data obtained from quantitative RT-PCR (Figure 8).
Furthermore, Ang-2 mRNA levels were upregulated robustly by
VEGF-Trap and moderately by DAAP in the tumors (Table S3).
In contrast, even during treatment with DAAP or VEGF-Trap,
Ang-1 mRNA levels were not upregulated in the tumor tissues
(Table S3). Given these results, the efficacy of DAAP seems to
largely depend on the inhibition of Ang-2, in addition to VEGF-A,
rather than Ang-1 in the tumors.DISCUSSION
In this study, we developed what we believe to be a DAAP that
simultaneously blocks VEGF-A/PlGF and angiopoietin. Although
the affinity of DAAP for VEGF-A is roughly three times lower than
its affinity for VEGF-Trap, it could be within the 5–10 pM range,
which is quite high compared to other decoy receptors and anti-
bodies against VEGF-A. However, the affinity of DAAP for Ang-2
is roughly five times higher than that of Tie2-Fc. Furthermore, the
binding of VEGF-A or Ang-2 to DAAP enhances its binding of
Ang-2 or VEGF-A, respectively, and could be a supplementary
benefit of using DAAP to block VEGF-A and Ang-2. Bioavail-
ability is of paramount importance in the systemic use of bioac-
tive molecules and developing therapeutic proteins. DAAP has
relatively high bioavailability and a longer half-life than VEGF-
Trap, raising the possibility that DAAP could be a superior
therapeutic protein to VEGF-Trap, assuming that it retained its
ability to simultaneously bind and block VEGF-A and angiopoie-
tins. Indeed, in suppressing tumor growth, angiogenesis, and
metastasis, DAAP was superior to the combined therapy of
VEGF-Trap plus Tie2-Fc, and DAAP was also superior to
VEGF-Trap when in combination with cytotoxic chemotherapy
agents such as cisplatin and dacarbazine. Based on these
results, we propose that the simultaneous blockade of VEGF-A
and Ang by DAAP can be an effective therapeutic strategy for
blocking tumor angiogenesis, metastasis, and vascular leakage.
Nevertheless, repeated DAAP treatment induced anticipated
toxicities such as thrombocytosis, hypertension and microalbu-
minuria and seem to correlate with the extent of endogenous
VEGF-A blockade (Lockhart et al., 2010; Tam et al., 2006;
Verheul and Pinedo, 2007). However, repeated administration
of DAAP did not generate autoantibodies to new epitopes
created at the junctions of elements from the different proteinsCancer Cell 18, 171–184, August 17, 2010 ª2010 Elsevier Inc. 179
Figure 7. DAAP Reduces Ascites Formation in OVCA
(A) Photographs showing the gross features of ascites formation on day 7 (upper panel) and 14 (lower panel) after MDAH-2774 cell implantation.
(B) Comparison of ascites volume. Each group, n = 5. *p < 0.05 versus Fc.
(C) Photographs showing Evans blue dye leakage in the intestines and abdominal walls. Scale bars represent 5 mm.
(D) Photographs showing the aspirated ascites before (upper panel) and after (lower panel) centrifugation. The red color indicates red blood cells, whereas the
blue color indicates Evans blue dye.
(E) Comparison of Evans blue amounts in the ascites. Each group, n = 5. *p < 0.05 versus Fc.
(F) Photographs showing FITC-dextran in 20 ml of ascites in two examples (1 and 2). B: blank well.
(G) Quantification of FITC-dextran in the ascites, expressed as radiance (photon/sec/cm2/steradian). Each group, n = 5. *p < 0.05 versus Fc.
(H) Photograph showing the gross features of tumor growth along the mesentery-intestinal border. T: tumor. Scale bars represent 5 mm.
(I) Comparison of tumor volume along the mesentery-intestinal border. Each group, n = 5. *p < 0.05 versus Fc; #p < 0.05 versus VT.
(J and K) Immunostaining micrographs for PECAM-1 showing the patterns of blood vessels in the peritoneum of the anterior mesenteric membrane and abdom-
inal wall. Normal, untreated normal mouse; Day 7 and 14, time after MDAH-2774 cell transplantation. T: tumor regions on the mesenteric membrane. Scale bars
represent 200 mm.
See also Figure S6.
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Figure 8. Close Correlation between DAAP Efficacy and Expression
of VEGF-A and Ang-2 in the Tumor Models
(A) Seven days after MDAH-2774 cell implantation (OVCA) or PBS injection
(Control) into athymic nude mice, the mesenteries were sampled. Tissue
lysates (100 mg of protein) and 100 ng of recombinant mouse Ang-2 were
analyzed by immunoblotting using an antimouse Ang-2 antibody. The
membrane was stripped and reprobed with anti-b-actin antibody. Three inde-
pendent experiments showed similar findings.
(B) Immunohistochemical localization of VEGFR2, Ang-2 and Tie2 in the intra-
and peritumoral regions 2 weeks after tumor cells implantation, liver was used
as a control. Scale bars represent 100 mm. Note that these are highly
expressed in tumor blood vessels.
(C) Ang-2 expression in implanted LLC and OVCA tumors in the Ang-2+/LZ
mice. Strong expression of Ang-2 (dark blue) is detected in tumor
blood vessels (white arrows) andmesenteric vessels (black arrow). In compar-
ison, expression of Ang-2 is strongly detected in the large-sized, but not
in small-sized mesenteric vessels, in normal condition. N: normal region; T:
tumor.
(D) Immunohistochemical localization of Ang-2 and Tie2 in the OVCA tumor.
Scale bars represent 100 mm. Note that these are highly expressed in the peri-
toneal blood vessels.
See also Tables S2 and S3.
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like other soluble receptors and therapeutic antibodies, DAAP is
unlikely to be an immunogenic protein.
These promising outcomes raise several intriguing questions.
First, what are the advantages of DAAP over combined therapy
with VEGF-Trap and Tie2-Fc and does DAAP have equivalent
benefits to the engineered fusion antibodies that contain more
than two binding sites (Wu et al., 2007)? Each protein has
a different biodistribution and half-life, which are sometimes
critical factors for effectiveness in anticancer therapy. DAAP
appeared to distribute well in the tumor environment and block
VEGF-A and Ang-2 in a synergistic manner, possibly with
increased ligand aggregation due to increased avidity effect
(Nowakowski et al., 2002). In contrast, because VEGF-Trap
and Tie2-Fc have different biodistributions and half-lives in the
body, they could not produce synergistic effects in the tumor
environment. Moreover, DAAP has a longer half-life than
VEGF-Trap and Tie2-Fc. A single anticancer agent could be
more cost-effective than dual anticancer agents. In this regard,
DAAP could have benefits equivalent to the engineered fusion
antibody.
Second, do all tumors highly express both VEGF-A/VEGFR2
and Ang/Tie2 systems, and are they activated in growing meta-
static tumors? If so, is it worthwhile to block both systems
to effectively suppress tumor angiogenesis and metastasis?
Accumulating evidence (Augustin et al., 2009; Ferrara and
Kerbel, 2005; Folkman, 2007; Huang et al., 2009; Shim et al.,
2007), including our findings, indicates that most tumors in
human patients and experimental animal models have high
expression and activation levels of both VEGF-A/VEGFR2 and
Ang/Tie2 and that these systems produce interactive synergistic
effects on tumor angiogenesis and metastasis. In particular,
consistent with our findings, numerous evidences indicate that
Ang-2, not Ang-1, is a major angiopoietin protein for enhancing
tumor angiogenesis along with several growth factors, including
VEGF-A. A recent report indicates that host-derived Ang-2
affects early tumor angiogenesis, although itmay be dispensable
for later tumor angiogenesis (Nasarre et al., 2009). Moreover, our
study showed that Ang-1 expression was not changed in the
growing tumor and even during treatment with DAAP or VEGF-
Trap. Tie2 signaling may also act directly on tumor cells in a
paracrine and autocrine manner; the receptor is being found
increasingly in tumor cells (Martin et al., 2008). Collectively, it
is worthwhile to doubly block angiopoietins in addition to
VEGF-A/PlGF to reduce tumor angiogenesis and metastasis.
Meeting this expectation and consistent with recent reports
(Brown et al., 2010; Hashizume et al., 2010), our results show
that double and simultaneous blockade of these ligands using
DAAP is highly effective in suppressing tumor angiogenesis
and metastasis compared to the single blockade of VEGF-A/
PlGF or Ang.
A third question is whyDAAP ismore effective than VEGF-Trap
in preventing vascular leakage in the OVCA mouse model.
VEGF-A is the primary molecule responsible for producing
ascites in OVCA, inducing vascular permeability in peritoneal
microvessels (Nagy et al., 1995). Ang-2 could be an additional
factor for the induction of ascites formation, enhancing the
destabilization and leakage of the peritoneal microvessels
(Parikh et al., 2006; Zhang et al., 2003). Our results suggest thatCancer Cell 18, 171–184, August 17, 2010 ª2010 Elsevier Inc. 181
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OVCA cells. Zhang et al. (2003) showed that OVCA-derived
VEGF-A upregulates Ang-2 in host endothelial cells, which could
result in further destabilization and leakage of the host vascula-
ture surrounding the tumors and peritoneum. Indeed, formation
of the unorganized, dense, and chaotic capillaries is prevalent
in the peritoneum of the abdominal wall in OVCA mice, which
is responsible for severe vascular leakage and ascites formation.
Given these changes in OVCA, our data suggest that the greater
anti-leak action of DAAP compared to VEGF-Trap may be partly
due to (1) enhanced normalization of tumor vessel (Jain, 2003);
(2) greater reduction in the unorganized, dense, and chaotic
vascular surface area due to tumor vessel pruning; (3) more
generalized improvement in endothelial barrier function; and (4)
less formation of ascites. Although DAAP could be considered
to disrupt the anti-leakage actions of Ang-1, the Ang-1 level for
counteracting Ang-2 was negligible in the OVCA mice. There-
fore, we strongly believe that the double blockade of VEGF-A
and Ang-2 with DAAP is more effective at preventing the forma-
tion of ascites in the OVCA mouse model than the single
blockade of VEGF-A by VEGF-Trap.
Fourth, could DAAP suppress the increased local invasion and
accelerated metastasis in anti-VEGF-A therapy-elicited malig-
nant tumorprogression? Incontrast to the largely knownconcept,
the blockade of VEGF-A-VEGFR2 signaling reduces primary
tumor growth but promotes tumor invasiveness and metastasis.
The increased expression of other proangiogenic factors,
including Ang-1, Ang-2, and fibroblast growth factors, a process
termed angiogenic rescue (Casanovas et al., 2005) could be
a main underlying mechanism for this phenomenon. These find-
ings reflect challenging clinical outcomes derived from the single
antiangiogenic therapy, suchasonlya short-termdelayof survival
rate, adaptive resistance, intrinsic nonresponsiveness, and the
rapid re-growth of tumor vessels after ceasing therapy (Bergers
and Hanahan, 2008;Mancuso et al., 2006). This fact was recently
highlighted in reports (Ebos et al., 2009; Loges et al., 2009; Paez-
Ribes et al., 2009). Combined therapy for antiangiogenesis and
antiproliferation is expanding experimentally in various cancer
models and clinically in numerous types of cancer patients. In
this regard, it should be noted that angiopoietins could be one
of the main factors for inducing tumor re-growth, adaptive resis-
tance, and accelerated metastasis during VEGF-A-VEGFR2
blockade (Huang et al., 2009). In this scenario, DAAP could be
a potential agent for suppressing the anti-VEGF-A therapy-eli-
cited malignant tumor progression.
Finally, there could be possible shortcomings of DAAP
compared to VEGF-Trap or specific anti-Ang-2 blocking anti-
body, such as (1) blocking the beneficial or antitumor effects of
Ang-1; (2) slower production rate in mammalian cells; (3) no
advantage in solely VEGF-A-dependent nontumor diseases;
or 4) no advantage in Ang-2-dependent tumor and nontumor
diseases. If one could develop an alternative DAAP variant that
selectively blocks VEGF-A and Ang-2, it could avoid the problem
of blocking the beneficial effect of Ang-1. However, we believe
our findings clearly indicate that tumor angiogenesis is mainly
dependent on both VEGF-A and Ang-2, not on Ang-1, in the
tumors we studied. Therefore, the application of DAAP deserves
to be diversified to various tumor models to determine the
possible benefits and effectiveness over VEGF-Trap.182 Cancer Cell 18, 171–184, August 17, 2010 ª2010 Elsevier Inc.In conclusion, DAAP is a chimeric decoy receptor that can
bind and block both VEGF-A and angiopoietins. By virtue of
this advantage, DAAP exhibits marked effectiveness in sup-
pressing the tumor angiogenesis and metastasis of implanted
and spontaneous solid tumors and in reducing ascites formation
and vascular leakage in advanced OVCA. Further preclinical
studies are warranted to explore additional applications of
DAAP for the control of pathologic angiogenesis, including
anti-VEGF-A therapy-elicited local invasion and metastasis.EXPERIMENTAL PROCEDURES
Measurement of Toxicity
Six-week-old male C57BL/6J mice (17 g body weight) were given subcuta-
neous injections of PBS, 25 mg/kg of Fc, VEGF-Trap, DAAP, or Tie2-Fc
recombinant protein every 3 days for 30 days. One day after the last treatment,
systolic blood pressure and heart rate were measured by an automated tail-
cuff device (IITC Life Science) under conscious state in a restrainer. Two
days after the last treatment, blood and urine samples were collected. Hemat-
ocrit wasmeasured by a hemocytometer (Heamatokrit 210, Hettich), WBC and
differential counts of WBC were measured by an automated CBC counter
(VetScan HM5 Hematology, ABXIS), and chemical analyses for blood and
urine were performed by a chemistry analyzer (VetTest 8008, IDEXX Laborato-
ries Inc.). Urinary albumin was measured by an immunoperoxidase assay
using The Albumin test kit according to the manufacturer’s instruction
(GenWay Biotech).
Generation of Tumor Models and Treatment Regimes
Specific pathogen-free C57BL/6J, Balb/C, MMTV-PyMT transgenic mice
(FVB/N), and BALB/cByJ athymic nude (CbyJ.Cg-Foxn1nu/J) were purchased
from Jackson Laboratory. All animals were bred in our pathogen-free animal
facility. Animal care and experimental procedures were performed with the
approval of the Animal Care Committee of KAIST. In particular, we performed
the melanoma experiments with special permission from the committee and
were allowed to grow the tumor until it reached 30% of the body weight to
assess the extent of metastasis to the lung.
Mouse LLC, B16/F10 melanoma, CT-26, and human MDAH-2774 ovarian
cancer cell lines were obtained from the American Type Culture Collection.
CT-26 cells (Balb/c background) were transduced with the luciferase gene
by a retroviral transfer, selected as a colony, and termed as ‘‘CT-26-luc’’ cells
(Dr. Kyung Keun Kim, Chonnam University, Korea).
To generate an implantation tumor model, a suspension (1 3 106 cells in
100 ml) of LLC or B16/F10 cells were subcutaneously implanted into the flank
region of C57BL/6J mice and a suspension (1 3 106 cells in 100 ml) of CT-26-
luc cells was orthotopically implanted into the dome of the cecal wall of Balb/c
mice. Indicated days later, the mice were given subcutaneous injections of
DAAP, VEGF-Trap, Tie2, or dimeric-Fc (indicated dose, frequency, and dura-
tion). As a control, an equal volume of PBS was injected in the same manner.
Indicated days later, the mice were anesthetized by intramuscular injection of
80 mg/kg ketamine and 12 mg/kg xylazine, tumor volumes were measured,
and primary tumors, indicated lymph nodes, lungs, and livers were harvested
for histological analyses. To administer a chemotherapeutic agent to the LLC
tumor model, intraperitoneal injections of cisplatin (10 mg/kg every 7 days;
Sigma-Aldrich) were performed 7 days after tumor implantation. To administer
a chemotherapeutic agent to the melanoma model, a treatment cycle con-
sisted of an intraperitoneal injection of dacarbazine (20 mg/kg; Sigma-Aldrich)
followed by an epifocal application of dinitrochlorobenzene (dissolved in a 4:1
mixture of acetone and olive oil) on the tumor 7 days after tumor implantation.
For the first cycle, the tumors were treated with 2% dinitrochlorobenzene,
whereas for the following cycles 1% dinitrochlorobenzene was used. Cycles
were repeated every 4 days. To compare the effect of DAAP on the established
LLC tumor, 14 days after implantation, the mice with equal sized (500 mm3)
tumors were chosen.
To generate an advanced OVCA model, a suspension of MDAH-2774 cells
(3 3 107 in 500 ml PBS) was injected into the peritoneal cavity of female
nude mice (Jeon et al., 2008). Seven days after injection, 5 ml of ascites
Cancer Cell
Double Antiangiogenic Proteinwas aspirated from the mice, and the mice were given four subcutaneous
injections of DAAP, VEGF-Trap, or dimeric-Fc (25 mg/kg) at every 2 days.
Heterozygous Ang-2+/LacZ mice (C57/BL/6J) were kindly provided by
Regeneron Pharmaceuticals. Mouse ovarian carcinoma cell line, ID-8
(C57BL/6J background), was kindly provided by Dr. Kathy Roby (University
of Kansas Medical Center). The cell lines were cultured in DMEM (GIBCO
BRL) containing 10% heat-inactivated FBS (HyClone), penicillin, and strepto-
mycin (Sigma-Aldrich) in plastic tissue culture dishes (Nunc) at 37C in a humid-
ified atmosphere of 5% CO2. To examine Ang-2 gene expression in tumors,
LLC cells (13 106 in 100 ml PBS) were subcutaneously implanted into the flank
region of Ang-2+/LacZ mice or ID-8 cells (1 3 107 in 500 ml PBS) were intraper-
itoneally implanted into Ang-2+/LacZ mice.
Vascular Leakage Assay in the OVCA model
Indicated days after MDAH-2774 cell implantation for generation of OVCA
model, the mice were anesthetized and administered Evans blue (80 mg/kg)
or 100 ml FITC-dextran (43,200 Da, 500 mg/ml) via the infraorbital plexus veins
to measure vascular permeability in the peritoneal cavities. Forty minutes after
the dye injection, the ascites was aspirated, its volume measured, and the
sample centrifuged at 14,0003 g. The Evans blue concentration in the ascites
was measured with a spectrophotometer using a Perkin-Elmer multi-plate
reader at 595 nm (Wallac Victor2V, Perkin-Elmer), and the fluorescence inten-
sity of FITC-dextran in the ascites was quantified in 50 ml of ascites from each
mouse using Living Image software (Xenogen) and expressed as radiance
(photon/sec/cm2/steradian).
Statistics
Values are presented as mean ± standard deviation (SD). Significant
differences between means were determined by an analysis of variance fol-
lowed by the Student-Newman-Keuls test. Statistical significance was set at
p < 0.05.
Additional experimental procedures, including generation of recombinant
proteins, ELISA, surface plasmon resonance assay, deglycosylation assay,
in vitro pull down assay, ECM binding assay, measurement of the pI value,
phosphorylation assay, inhibition assay for endothelial cell proliferation, phar-
macokinetic analysis, luminographic imaging of tumor size, histological and
morphometric analysis, and endothelial cell sorting and quantitative real-
time PCR, are listed in the Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.ccr.2010.07.001.
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